百奧泰(688177.SH):美泊利珠單抗注射液(BAT2606)獲批開展臨牀試驗
格隆匯3月25日丨百奧泰(688177.SH)公佈,公司於近日收到國家藥品監督管理局核准簽發的關於公司在研藥品美泊利珠單抗注射液(BAT2606)的《臨牀試驗批准通知書》。
BAT2606注射液作為一種美泊利珠單抗注射液的生物類似藥,活性成分為重組人源化免疫球蛋白G1(IgG1)單克隆抗體,可特異性結合人IL-5,阻斷IL-5與表達於嗜酸性粒細胞表面受體複合體α鏈結合,抑制IL-5的生物活性,能夠降低血液、組織、痰液中的嗜酸性粒細胞水平,從而降低嗜酸性粒細胞所介導的炎症。該炎症是哮喘、CRSwNP、EGPA和HES發病機制中的重要組分。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.